PMA device
Zephyr Endobronchial Valve System
Pulmonx Corporation · Valve, Pulmonary (NJK, Class III) · First FDA decision Jun 29, 2018, newest Mar 22, 2024COPD and emphysema
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
18
Naming "Zephyr Endobronchial"
MAUDE reports
1,719
Brand "Zephyr Endobronchial", since 2015
PubMed studies
21
Mentioning "Zephyr Endobronchial"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Zephyr Endobronchial Valve System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Zephyr Endobronchial Valve SystemPMA supplement
P180002-S025 · Decided Mar 22, 2024 · 92 days after receipt · Normal 180 Day Track No User Fee
Device type: Valve, pulmonary (NJK) · Anesthesiology & Respiratory
- Zephyr Endobronchial Valve (Zephyr Valve)PMA supplement
P180002-S019 · Decided Aug 13, 2021 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Valve, pulmonary (NJK) · Anesthesiology & Respiratory
- Zephyr Endobronchial Valve (EBV) SystemPMA supplement
P180002-S005 · Decided Jul 30, 2019 · 225 days after receipt · Normal 180 Day Track
Device type: Valve, pulmonary (NJK) · Anesthesiology & Respiratory
3 more FDA decisions with a free account
Older decisions: P180002
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Zephyr Endobronchial", any status and sponsor, newest update first.
- Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in EmphysemaActive, not recruiting
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT04801108 · 20 participants (planned) · Start Aug 1, 2021 · Primary completion Dec 31, 2026
Device: Endobronchial valves placement · For: Emphysema or COPD
Sites: Boston, Massachusetts
Pulmonx CorporationPublic (LUNG)
NCT06332885 · 140 participants (planned) · Start Mar 12, 2024 · Primary completion Mar 31, 2027
Device: Zephyr Endobronchial Valve · For: Emphysema; COPD; Severe Emphysema
Sites: Aichi, Japan; Gifu, Japan; Kanagawa, Japan · 17 sites in all
- Zephyr Valve Registry (ZEVR)Active, not recruiting
Pulmonx CorporationPublic (LUNG)
NCT04186546 · 150 participants (planned) · Start Nov 25, 2019 · Primary completion Dec 31, 2026
Device: Zephyr Valve Procedure · For: Emphysema
Sites: Birmingham, Alabama; Chicago, Illinois; Winfield, Illinois · 11 sites in all
15 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Zephyr Endobronchial", and for the whole product code for context.
This brand
1,719 reports: 113 malfunction, 1,433 injury, 173 death
Whole product code NJK
2,041 reports: 124 malfunction, 1,732 injury, 185 death
Newest reports for this brand
3007797756-2026-00061 · Received Oct 15, 2026 · Event dated Sep 21, 2026
Device type: Valve, Pulmonary (NJK)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
3007797756-2026-00062 · Received Oct 15, 2026 · Event dated Sep 22, 2026
Device type: Valve, Pulmonary (NJK)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
3007797756-2026-00060 · Received Oct 15, 2026 · Event dated Sep 21, 2026
Device type: Valve, Pulmonary (NJK)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Zephyr Endobronchial Valve (EBV) 5.5-LP, REF: EBV-TS-5.5-LPOpen, Classified
Z-0235-2024 · Started Aug 31, 2023 · Posted by FDA Nov 6, 2023
Reason given: Endobronchial implant devices may have been labeled with a shortened expiration date but they can be used until the correct expiration date: 08 December 2024.
Cause as FDA categorized it: Error in labeling · Device type: Valve, Pulmonary (NJK)
Published research
The most relevant PubMed records for "Zephyr Endobronchial"[tiab]. The summary above synthesizes these.
- A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE).
Criner GJ, Sue R, Wright S, et al. · Am J Respir Crit Care Med · 2018Multicenter Study, Randomized Controlled Trial
- Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial.
Eberhardt R, Slebos DJ, Herth FJF, et al. · Respiration · 2021Randomized Controlled Trial
- Device profile of the Zephyr endobronchial valve in heterogenous emphysema: overview of its safety and efficacy.
Verga SR, Criner GJ · Expert Rev Med Devices · 2021Review
- A 6-year experience of Zephyr endobronchial valves for severe emphysema in an Australian single-centre cohort.
Brown MV, Badiei A, Jersmann H, et al. · Intern Med J · 2024
- Endobronchial valves: 1st Multicenter retrospective study on the 2-step approach.
Egenod T, Guibert N, Ammar Y, et al. · Respir Med Res · 2023Multicenter Study
- Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial.
Dransfield MT, Garner JL, Bhatt SP, et al. · Ann Am Thorac Soc · 2020Multicenter Study, Randomized Controlled Trial
- Remimazolam for Zephyr Endobronchial Valve Placement in a Severe Chronic Obstructive Pulmonary Disease Patient: A Case Report.
Morimoto T, Ichinomiya T, Tobinaga S, et al. · Clin Case Rep · 2026
- A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).
Kemp SV, Slebos DJ, Kirk A, et al. · Am J Respir Crit Care Med · 2017Multicenter Study, Randomized Controlled Trial
- Clinical outcomes and quantitative CT analysis after bronchoscopic lung volume reduction using valves for advanced emphysema.
Guo F, Huang J, Hu Y, et al. · J Thorac Dis · 2022
- Use of endobronchial valve insertion to treat relapsing pneumothorax: a case report and literature review.
Qi F, Tian Q, Chen L, et al. · Clin Respir J · 2017Case Reports, Review
- Patient Preferences for Endobronchial Valve Treatment of Severe Emphysema.
Mansfield C, Sutphin J, Shriner K, et al. · Chronic Obstr Pulm Dis · 2018
- Unidirectional endobronchial valves for management of persistent air-leaks: results of a multicenter study.
Fiorelli A, D'Andrilli A, Cascone R, et al. · J Thorac Dis · 2018
Other devices of this type
Also filed under product code NJK.
- Spiration® Valve SystemGyrus Acmi, Inc. · PMA 2026
- Zephyr Valve Reigstry (ZEVR)Pulmonx Corporation · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.